Congratulations to the team at #FlagshipFounded Empress Therapeutics on being named to C&EN (Chemical & Engineering News)’s list of startups to watch. #10StartUpsToWatch Learn more about how Empress is converging the power of genetics and a digital data-driven AI approach to revolutionize small molecule drug

How does Empress' genetics-first approach set us apart from others in the field? Our CEO, Jason Park, spoke to GenomeWeb about seeking out and optimizing molecules produced by our microbiomes that already play therapeutic roles within our bodies to streamline the #drugdiscovery

Could AI change the paradigms of drug discovery? Definitely, argues Empress co-founder & CIO Sabrina Yang. Not only can it drive speed and cost savings, #AI is already enabling things that were not possible before, such as directly predicting chemical structures from DNA

Where ChatGPT goes from text to text, the Empress Chemilogics™ platform takes us from the code of DNA to chemistry, by way of the enzymes involved in chemical synthesis and modification. In this excellent @EPM_magazine interview, Empress SVP of Drug Discovery Kevin Kreutter

Can the way our bodies react to the metabolites we are exposed to every day teach us how to heal ourselves? This is one of the big questions Dr. Jun Huh, associate professor in immunology at @Harvardmed, is eager to answer. We were delighted to hear about his explorations so far

Is it time to extend the central dogma of biology (i.e. DNA ➡️ RNA ➡️ proteins) to chemistry to include small molecule products of proteins? Yes, argues Empress CEO Jason Park Jason Park in this Drug Discovery World editorial, where he advocates for searching the human metagenome to

How is the pharmaceutical industry integrating innovations from adjacent industries or markets to enhance drug development and production? Empress Co-Founder and Chief Innovation Officer Sabrina Yang, says: just as generative #AI applications like ChatGPT have transformed the

This holiday season, we’re toasting to the incredible team behind Empress Therapeutics! 🥂 We’re so proud to work alongside such innovative, passionate, and talented individuals. Here’s to a joyful holiday season and a groundbreaking year ahead!

2024 was a year of breakthroughs and bold strides at Empress. By leveraging the human metagenome to unlock nature’s evolutionary-scale database, we’ve set the stage for transformative drug discovery. This year, our pioneering platform delivered unprecedented

Nature has long been a master chemist, crafting solutions over millennia. At Empress Therapeutics, we harness this intelligence, combining it with AI and human insight to transform drug discovery. This synthesis of #polyintelligence, as beautifully articulated by Noubar Afeyan,

At the #FlagshipJPM CEO Chat, Empress CEO Jason Park shared how the company’s #Chemilogics platform is rewriting the rules of small molecule drug discovery. 🔬 Platform Differentiation: Empress combines genetics, co-evolution, AI, and synthetic biology to decode how DNA programs

From pipeline developments and clinical milestones to new partnerships, hear from the CEOs and leaders of #FlagshipFounded companies advancing novel science and platforms to make #BiggerLeaps for human health. Watch all the conversations: flagshippioneering.com/topics/ceo-cha… 🔹 Lovisa

Medicine designed within the context of a patient’s disease? It sounds straightforward, but the reality is far more complex. SVP of Biology Joe Kelleher talks to Drug Discovery News about how Empress is using AI and machine learning—anchored in human clinical data and genetic

🧧 恭喜发财 𝗛𝗮𝗽𝗽𝘆 𝗟𝘂𝗻𝗮𝗿 𝗡𝗲𝘄 𝗬𝗲𝗮𝗿 from #TeamEmpress, who came together this week to celebrate with our own mini money tree and treats. May the year ahead be healthy and prosperous for you all! 新年快樂 🐍

Meryl Kelada comes from a long line of physicians & scientists, and her biochemist grandmother helped spark her curiosity in science from a young age. Now a chemical biologist herself, Meryl shared her advice for other aspiring #WomeninScience for #IDWGS. #TeamEmpress

For #IDWGS, we chatted with automation engineer Kate Rooney from #TeamEmpress about how to empower current and aspiring female scientists. The robotics expert says mentorship is key for #WomeninSTEM. See what else she had to say in this short video. #CareersinSTEM

If there’s a problem you care about, go solve it. That's the advice of Shannon McArdel, our Director of Immunology, whose mother's struggle with a progressive, debilitating disease motivated her to pursue a career in science. For #IDWGS, she shares her journey and advice for

𝗛𝘆𝗽𝗲 𝗼𝗿 𝗛𝗼𝗽𝗲? Empress CSO Murray McKinnon weighs in on whether he thinks AI is truly transforming drug development in this Pharma's Almanac Q&A. 🔗 pharmasalmanac.com/articles/is-ai…

Evolution has shaped microbes to program the body in ways traditional pharma rarely considers. Dr. Josh Rabinowitz believes we can learn a great deal from nature’s own medicinal chemistry, and we were delighted to have the esteemed Princeton University chemistry professor join us

We’re proud to celebrate Kevin Kreutter, Empress SVP of Drug Discovery, for being named to The Medicine Maker 2025 Power List. Kevin’s deep expertise in small molecule drug discovery has been instrumental to our mission: using genetics and AI to uncover drug-like molecules